Dow Jones
38.111,48 -330,06 (-0,86%) Nasdaq
16.737,08 -183,50 (-1,08%) Nikkei 225
38.216,34 +162,21 (+0,43%) EUR/USD
1,0830 -0,0006 (-0,05%) Bitcoin EUR
63.271,51 +807,12 (+1,29%) CMC Crypto 200
1.431,88 -23,99 (-1,65%)
Biomea Fusion, Inc. (BMEA)
Dopo ore:
| Chiusura precedente | 10,89 |
| Aperto | 10,96 |
| Denaro | 10,39 x 100 |
| Domanda | 10,51 x 100 |
| Min-Max giorno | 10,15 - 11,18 |
| Intervallo di 52 settimane | 8,12 - 43,69 |
| Volume | |
| Media Volume | 1.004.526 |
| Capitalizzazione | 391,796M |
| Beta (mensile su 5 anni) | -0,35 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -3,41 |
| Prossima data utili | 01 apr 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 54,43 |
GlobeNewswireBiomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for BMF-219 in Type 1 Diabetes
BMF-219 is a novel covalent menin inhibitor designed to regenerate insulin-producing beta cells with the aim to cure type 1 diabetesThe FDA has cleared the initiation of COVALENT-112, a Phase II clinical trial of BMF-219 in adults with type 1 diabetes (T1D).The randomized, double-blind, placebo-controlled (N=150) trial in adults with T1D will examine the safety and efficacy of BMF-219 at two oral dose levels, 100 mg and 200 mg unfed, for 12-weeks of treatment followed by a 40 week off-treatment
- GlobeNewswire
Biomea Fusion Announces FDA and Health Canada Clearance of the Expansion Cohorts of the Ongoing COVALENT-111 Phase II Study
The FDA and Health Canada have cleared the initiation of the expansion portion of COVALENT-111, which will evaluate BMF-219 administered at 100 mg and 200 mg, with dosing durations up to 12 weeks in type 2 diabetes patientsThe expansion portion will consist of approximately 300 patients and will begin to enroll three cohorts immediately, with a fourth cohort following the completion of the escalation portionCompared to baseline, 84% of all patients dosed for four weeks with BMF-219 (n=32) in the
- GlobeNewswire
Biomea Fusion Announces Appointment of Juan Pablo Frías, M.D. as Chief Medical Officer
Industry veteran and prominent diabetes clinical development expert to oversee Biomea’s progressing clinical development of novel covalent menin inhibitor BMF-219 in type 2 and type 1 diabetesSteve Morris, M.D., will transition to the role of Chief Development Officer, continuing to lead clinical development of Biomea’s oncology portfolio, including BMF-219, BMF-500 and research-stage assets REDWOOD CITY, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a
